Acciones Immunoprecise Antibodies Ltd Toronto S.E.
Acciones
TQY
CA87588T2020
Farmacéuticos
Ventas 2024 * | 24,59 M 18,02 M 16,65 M | Ventas 2025 * | 29,82 M 21,85 M 20,19 M | Capitalización | 43,1 M 31,58 M 29,19 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -12 M -8,79 M -8,13 M | Resultado Neto 2025 * | -9 M -6,59 M -6,09 M | VE / Ventas 2024 * | 1,75 x |
Posición de caja neta 2024 * | - 0 0 | Posición de caja neta 2025 * | - 0 0 | VE / Ventas 2025 * | 1,45 x |
P/E ratio 2024 * |
-3,42
x | P/E ratio 2025 * |
-4,63
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 86,41 % |
Último transcript sobre Immunoprecise Antibodies Ltd
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
-1,21 % | 89,37 mil M | |
+2,76 % | 40,65 mil M | |
-12,32 % | 32,81 mil M | |
+52,41 % | 25 mil M | |
-17,39 % | 15,29 mil M | |
-42,45 % | 11,61 mil M | |
-10,48 % | 11,49 mil M | |
+6,14 % | 8981,89 M | |
-7,72 % | 8226,73 M |